Modern treatment of bronchial asthma
https://doi.org/10.24884/1609-2201-2025-104-3-11-18
Abstract
Review is focused on modern treatment of asthma, one of the most prevalent and significant respiratory diseases in the world. Goals of long-term asthma management and different treatment tracks for symptoms control and risk reduction based on international and national recommendations are discussed.
About the Authors
A. V. Emelianov
North-Western State Medical University named after I. I. Mechnikov
Russian Federation
Russian Federation
Aleksandr V. Emelianov, Dr. of Sci. (Med.), Professor, Head of the Pulmonology Department
Saint Petersburg
E. V. Leshenkova
North-Western State Medical University named after I. I. Mechnikov
Russian Federation
Russian Federation
Evgeniya V. Leshenkova, Cand. of Sci. (Med.), Associate Professor, Pulmonology Department
41, Kirochnaya St., Saint-Petersburg, 191015
G. R. Sergeeva
North-Western State Medical University named after I. I. Mechnikov
Russian Federation
Russian Federation
Galina R. Sergeeva, Cand. of Sci. (Med.), Associate Professor, Department of Pulmonology
Saint Petersburg
I. V. Tsukanova
North-Western State Medical University named after I. I. Mechnikov
Russian Federation
Russian Federation
Inessa V. Tsukanova, Cand. of Sci. (Med.), Assistant Professor, Department of Pulmonology
Saint Petersburg
References
1. Global Strategy for Asthma Management and Prevention. Revised 2025. URL: https://www.ginasthma.org (accessed: 25.07.2025).
2. Bronchial asthma. National clinical guidelines. 2024 URL: https://cr.minzdrav.gov.ru/recomend/359_2 (accessed: 25.07.2025). (In Russ.).
3. Prieto L., Badiola C., Villa J. R. et al. Asthma Control: Do Patients’ and Physicians’ Opinions Fit in with Patients’ Asthma Control Status? Journal of Asthma. 2007;44:461–467. https://doi.org/10.1080/02770900701421989.
4. Urrutia I., Plaza V., Pascual S. et al. Asthma control and concordance of opinions between patients and pulmonologists. Journal of Asthma. 2013;50(8):877–883. https://doi.org/10.3109/02770903.2013.819886.
5. Stridsman C., Axelsson M., Warm K., Backman H. Uncontrolled asthma occurs in all GINA treatment steps and is associated with worse physical health — A report from the OLIN adult asthma cohort. Journal of Asthma. 2020:1–16. https://doi.org/10.1080/02770903.2020.1713150.
6. Thomas D., McDonald V. M., Pavord I. D., Gibson P. G. Asthma remission: what is it and how can it be achieved? The European Respiratory Journal. 2022;60(5):2102583. https://doi.org/10.1183/13993003.02583-2021.
7. Lotvall J., Akdis C.A., Bacharier L. B. et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. JACI. 2011;127:355–360. https://doi.org/10.1016/j.jaci.2010.11.037.
8. Fedoseyev G. B., Trofimov V. I., Petrova M. A. The many-sided bronchial asthma, diagnosis, treatment and prevention. Saint-Peterburg, Nordmedizdat, 2011. 344 p. (In Russ.).
9. Bousquet J., van Cauwenberge P., Khaltaev N. Allergic rhinitis and its impact on asthma (ARIA). ARIA. At a glance pocket reference, 1st Edition. 2007. 6 p.
10. Sobieraj D. M., Weeda E. R., Nguyen E. et al. Association of Inhaled Corticosteroids and Long-Acting β-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma. A Systematic Review and Meta-analysis. JAMA. 2018;319(14):1485–1496. https://doi.org/10.1001/jama.2018.2769.
11. Lee L. A., Bailes Z., Barnes N. et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. The Lancet Respiratory Medicine. 2021;9(1):69–84. https://doi.org/10.1016/s2213-2600(20)30389-1.
12. Woodcock A., Vestbo J., Bakerly N. D. et al. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial. The Lancet. 2017;390(10109):2247–2255. https://doi.org/10.1016/s0140-6736(17)32397-8.
13. McCracken J., Tripple J., Calhoun W. Biologic therapy in the management of asthma. Curr Opin Allergy Clin Immumol. 2016;16(4):375–382. https://doi.org/10.1097/aci.0000000000000284.
14. Pelaia C., Vatrella A., Bruni A. et al. Benralizumab in the treatment of severe asthma: design, development and potential place in therapy. Drug design, development and therapy. 2018;12:619–628. https://doi.org/10.2147/dddt.s155307.
15. Lugogo N., Domingo C., Chanez P. et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. Clinical Therapeutics. 2016;38(9):2058–2070. https://doi.org/10.1016/j.clinthera.2016.07.010.
16. Castro M., Corren J., Pavord I. D. et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018;378:2486–2496. https://doi.org/10.1056/nejmoa1804092.
17. Agache I., Akdis C., Akdis M. et al. EAACI Biologicals Guidelines-Recommendations for severe asthma. Allergy. 2021;76(1):14–44. https://doi.org/doi.org/10.1111/all.14425.
18. Severe bronchial asthma. Clinical guidelines of the Association of Russian-speaking specialists in the respiratory medicine. Мoscow, 2018. URL: https://spulmo.ru/obrazovatelnye-resursy/federalnye-klinicheskie-rekomendatsii/ (accessed: 25.07.2025). (In Russ.).
19. Bousquet J., Brusselle G., Buhl R. et al. Care pathways for the selection of a biologic in severe asthma. Eur Respir J. 2017;50:1701782. https://doi.org/10.1183/13993003.01782-2017.
20. Menzies-Gow A., Corren J., Bourdin A. et al. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. N Engl J. 2021;384:1800–1809. https://doi.org/10.1056/nejmoa2034975.
21. Wechsler M. E., Ruddy M. K., Pavord J. D. et al. Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. N Engl J Med. 2021;385(18):1656–1668. https://doi.org/10.1056/nejmoa2024257.
22. Kelsen S. G., Agache J. O., Soong W. et al. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial. J Allergy Clin Immunol. 2021;148(3):790–798. https://doi.org/10.1016/j.jaci.2021.03.044.
23. Emelyanov A. V. Rational therapy of bronchial asthma. Moscow, GEOTAR-Media, 2025. 280 p.: ill. (In Russ.). https://doi.org/10.33029/9704-8825-6-RTA-2025-1-280.
24. Jarjour N. N., Erzurum S. C., Bleecker E. R. et al. Severe asthma: lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program. Am J Respir Crit Care Med. 2012;185(4):356–362. https://doi.org/10.1164/rccm.201107-1317pp.
25. Sergeeva G. R., Emelyanov A. V., Korovina O. V. et al. Severe asthma: Characteristics of patients in clinical practice. Terapevticheskii Arkhiv. 2015;12:22–27. (In Russ.). https://doi.org/10.17116/terarkh2015871226-31.
26. Fedoseev G. B., Trofimov V. I., Shaporova N. L. et al. Searching the truth: what is bronchial asthma? Pulmonologiya. 2015;25(1):5–18. (In Russ.). https://doi.org/10.18093/0869-0189-2015-25-1-5-18.
27. Rajan J. P., Wineinger N. E., Stevenson D. D., White A. A. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature. J Allergy Clin Immunol. 2015;135(3):676. https://doi.org/10.1016/j.jaci.2014.08.020.
28. Sergeeva G. R., Emel’yanov A. V., Leshenkova E. V. et al. Fixed airflow obstruction in patients with asthma. Pulmonologiya. 2020;30(3):295–304. (In Russ.). https://doi. org/10.18093/0869-0189-2020-30-3-295-304.
29. ten Brinke A., Zwinderman A. H., Sterk P. J. et al. Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med. 2001;164(5):744–748. https://doi.org/10.1164/ajrccm.164.5.2011026.
30. Lee J. H., Haselkorn T., Borish L. et al. Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study. Chest. 2007;132:1882–9. https://doi.org/10.1378/chest.07-0713.
31. Pappi A., Singh D., Virchow J. C. et al. Normalisation of airflow limitation in asthma: Post-hoc analyses of TRIMARAN and TRIGGER. Clin Transl Allergy. 2022;12(4):e12145. https://doi.org/10.1002/clt2.12145.
32. Peters U., Dixon A. E., Forno E. Obesity and asthma. JACI. 2018;141(4):1169–1179. https://doi.org/10.1016/j.jaci.2018.02.004.
33. Dixons A., Que L. Obesity and Asthma.Semin Respir. Crit Care Med. 2022;43(05):662–674. https://doi.org/10.1055/s-0042-1742384.
34. Menzies-Gow A., Gurnell M., Heaney L. G. et al. Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study. Lancet Respir Med. 2022;10(1):47–58. https://doi.org/10.1016/s2213-2600(21)00352-0.
35. Romero-Tapia S. J., Priego C. G., Del-Río-Navarro B. E., Sánchez-Solis M. Advances in the Relationship between Respiratory Viruses and Asthma. J. Clin. Med. 2023;12:5501. https://doi.org/10.3390/jcm12175501.
36. Crapo R. O., Casaburi R., Coates A. L. et al. Guidelines for Methacholine and Exercise Challenge Testing—1999. American Journal of Respiratory and Critical Care Medicine. 2000;161(1): 309–329. https://doi.org/10.1164/ajrccm.161.1.ats11-99.
37. Price D., Popov T. A., Bjermer L. et al. Effect of montelukast for treatment of asthma in cigarette smokers. J Allergy Clin Immun. 2013;131(3):763–771. https://doi.org/10.1016/j.jaci.2012.12.673.
38. Price D., Popov T. A., Bjermer L. et al. Effect of montelukast for treatment of asthma in cigarette smokers // J Allergy Clin Immun. 2013. Vol. 131, № 3. P. 763–771. https://doi.org/10.1016/j.jaci.2012.12.673.
39. Price D., Popov T. A., Bjermer L. et al. Effect of montelukast for treatment of asthma in cigarette smokers. J Allergy Clin Immun. 2013;131(3):763–771. https://doi.org/10.1016/j.jaci.2012.12.673.
Review
For citations:
Emelianov A.V., Leshenkova E.V., Sergeeva G.R., Tsukanova I.V. Modern treatment of bronchial asthma. New St. Petersburg Medical Records. 2025;(3):11-18. (In Russ.) https://doi.org/10.24884/1609-2201-2025-104-3-11-18
Views:
60
Email this article 